Found: 63
Select item for more details and to access through your institution.
Anti‐IL17 Secukinumab in hidradenitis suppurativa: A long‐term drug survival analysis.
- Published in:
- Experimental Dermatology, 2024, v. 33, n. 7, p. 1, doi. 10.1111/exd.15140
- By:
- Publication type:
- Article
Drug survival, effectiveness, and safety of brodalumab for moderate‐to‐severe psoriasis up to 3 years.
- Published in:
- International Journal of Dermatology, 2024, v. 63, n. 7, p. 922, doi. 10.1111/ijd.17038
- By:
- Publication type:
- Article
Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience.
- Published in:
- Journal of Personalized Medicine, 2024, v. 14, n. 7, p. 718, doi. 10.3390/jpm14070718
- By:
- Publication type:
- Article
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis).
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 6, p. 1649, doi. 10.1007/s13555-024-01182-4
- By:
- Publication type:
- Article
Awareness of obesity among patients with psoriasis.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 5, p. e391, doi. 10.1111/jdv.19617
- By:
- Publication type:
- Article
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 4, p. 919, doi. 10.1007/s13555-024-01135-x
- By:
- Publication type:
- Article
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 2, p. 333, doi. 10.1007/s40257-024-00845-4
- By:
- Publication type:
- Article
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2023.1341708
- By:
- Publication type:
- Article
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS).
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 2, p. 495, doi. 10.3390/jcm13020495
- By:
- Publication type:
- Article
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2024, v. 22, n. 1, p. 34, doi. 10.1111/ddg.15251
- By:
- Publication type:
- Article
Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2024, v. 22, n. 1, p. 34, doi. 10.1111/ddg.15251_g
- By:
- Publication type:
- Article
Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 24, p. 7503, doi. 10.3390/jcm12247503
- By:
- Publication type:
- Article
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 3561, doi. 10.2147/CCID.S416149
- By:
- Publication type:
- Article
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 12, p. 2187, doi. 10.1111/exd.14731
- By:
- Publication type:
- Article
Achievement and maintenance of therapeutic response to brodalumab in patients with moderate‐to‐severe plaque psoriasis: An Italian, observational, retrospective and prospective study (BRIGHT study).
- Published in:
- JEADV Clinical Practice, 2023, v. 2, n. 4, p. 739, doi. 10.1002/jvc2.204
- By:
- Publication type:
- Article
Aging Impact in Response to Different Classes of Biological Treatment in Psoriatic Patients: A Real-Life Observational Study.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 23, p. 7215, doi. 10.3390/jcm12237215
- By:
- Publication type:
- Article
Exploring Psoriasis Inflammatory Microenvironment by NanoString Technologies.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study.
- Published in:
- Dermatologic Therapy, 2023, p. 1, doi. 10.1155/2023/1793535
- By:
- Publication type:
- Article
Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 10, p. e1203, doi. 10.1111/jdv.19186
- By:
- Publication type:
- Article
The Skin Microbiome and Its Role in Psoriasis: A Review.
- Published in:
- Psoriasis: Targets & Therapy, 2023, v. 13, p. 71, doi. 10.2147/PTT.S328439
- By:
- Publication type:
- Article
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real‐life experience on 638 patients with psoriasis.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 9, p. 1591, doi. 10.1111/exd.14874
- By:
- Publication type:
- Article
Exacerbation of acquired perforating dermatosis following SARS‐CoV‐2 vaccination.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 9, p. e1091, doi. 10.1111/jdv.19137
- By:
- Publication type:
- Article
Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 7, p. 3021, doi. 10.1007/s12325-023-02516-y
- By:
- Publication type:
- Article
Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi Consensus.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 6, p. 1219, doi. 10.1007/s13555-023-00930-2
- By:
- Publication type:
- Article
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 10, p. 3545, doi. 10.3390/jcm12103545
- By:
- Publication type:
- Article
Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 5, p. 1017, doi. 10.1111/jdv.18913
- By:
- Publication type:
- Article
Intraclass Switching among IL17 Inhibitors in Psoriasis: A Real-Life, Long-Term Single-Center Experience.
- Published in:
- Dermatologic Therapy, 2023, p. 1, doi. 10.1155/2023/5557255
- By:
- Publication type:
- Article
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents.
- Published in:
- Clinical & Experimental Dermatology, 2023, v. 48, n. 4, p. 379, doi. 10.1093/ced/llac098
- By:
- Publication type:
- Article
Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 847, doi. 10.2147/CCID.S400520
- By:
- Publication type:
- Article
Characteristics of Patients Experiencing a Flare of Generalized Pustular Psoriasis: A Multicenter Observational Study.
- Published in:
- Vaccines, 2023, v. 11, n. 4, p. 740, doi. 10.3390/vaccines11040740
- By:
- Publication type:
- Article
Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 4, p. 1662, doi. 10.3390/jcm12041662
- By:
- Publication type:
- Article
Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study.
- Published in:
- Acta Dermato-Venereologica, 2023, v. 103, p. 1, doi. 10.2340/actadv.v103.4526
- By:
- Publication type:
- Article
Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study.
- Published in:
- Acta Dermato-Venereologica, 2023, v. 103, p. 1, doi. 10.2340/actadv.v103.5278
- By:
- Publication type:
- Article
Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 1, p. 93, doi. 10.1111/jdv.18594
- By:
- Publication type:
- Article
Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real‐life experience and therapeutic response to other biological drugs.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 12, p. 1, doi. 10.1111/dth.15866
- By:
- Publication type:
- Article
Topical cyclosporine hydrogel preparation: A new therapeutic option in the treatment of nail psoriasis.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 12, p. 1, doi. 10.1111/dth.15917
- By:
- Publication type:
- Article
Long‐term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach.
- Published in:
- International Journal of Dermatology, 2022, v. 61, n. 12, p. 1543, doi. 10.1111/ijd.16192
- By:
- Publication type:
- Article
Tildrakizumab in real‐life shows good efficacy in moderate‐to‐severe psoriasis regardless of previous use of biologic drugs and joint involvement.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 11, p. 1, doi. 10.1111/dth.15818
- By:
- Publication type:
- Article
Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 11, p. 1, doi. 10.1111/dth.15803
- By:
- Publication type:
- Article
Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 11, p. 2613, doi. 10.1007/s13555-022-00797-9
- By:
- Publication type:
- Article
Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study.
- Published in:
- Biomedicines, 2022, v. 10, n. 10, p. N.PAG, doi. 10.3390/biomedicines10102522
- By:
- Publication type:
- Article
Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real‐life study.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 10, p. 1, doi. 10.1111/dth.15670
- By:
- Publication type:
- Article
Switching from IL23 inhibitors to IL17 inhibitors: A safe and effective practice?
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 9, p. 1, doi. 10.1111/dth.15697
- By:
- Publication type:
- Article
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis.
- Published in:
- Dermatology Reports, 2022, v. 14, n. 3, p. 1, doi. 10.4081/dr.2022.9282
- By:
- Publication type:
- Article
Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population.
- Published in:
- British Journal of Dermatology, 2022, v. 187, n. 2, p. 263, doi. 10.1111/bjd.21048
- By:
- Publication type:
- Article
Real life long‐term efficacy and safety of ixekizumab in moderate‐to‐severe psoriasis: A 192 weeks multicentric retrospective study—IL PSO (Italian landscape psoriasis).
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 8, p. 1, doi. 10.1111/dth.15608
- By:
- Publication type:
- Article
Efficacy and safety of Dimethyl fumarate in comparison with conventional therapy for psoriasis: an Italian real‐world clinical experience.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2022, v. 36, n. 7, p. e534, doi. 10.1111/jdv.17997
- By:
- Publication type:
- Article
Persistent eruptive lentiginosis in a psoriatic patient after 4‐year effective treatment with ustekinumab.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 6, p. 1, doi. 10.1111/dth.15468
- By:
- Publication type:
- Article
Risankizumab shows high efficacy and maintenance in improvement of response until week 52.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 5, p. 1, doi. 10.1111/dth.15378
- By:
- Publication type:
- Article
Certolizumab pegol and its role in pregnancy‐age hidradenitis suppurativa.
- Published in:
- International Journal of Dermatology, 2022, v. 61, n. 5, p. e182, doi. 10.1111/ijd.15742
- By:
- Publication type:
- Article